Sign Out
Pregnancy: There are no data on the use of aflibercept in pregnant women.
Studies in animals have shown reproductive toxicity after systemic administration.
Aflibercept (Eylea) should not be used during pregnancy unless the potential benefit outweighs the potential risk to the fetus.
Women of childbearing potential: Women of childbearing potential have to use effective contraception during treatment and for at least 3 months after the last intravitreal injection of Aflibercept (Eylea).
Lactation: It is unknown whether aflibercept is excreted in human milk. A risk to the breast-fed child cannot be excluded.
Aflibercept (Eylea) is not recommended during breast-feeding. A decision must be made whether to discontinue breast-feeding or to abstain from Aflibercept (Eylea) therapy.
Continue with Google